QuidelOrtho (TICKER: QDEL) Benchmark And Performance Data

there are 11 of samples in the benchmark for QuidelOrtho in year 2022 in 2022. The total inventory for QuidelOrtho was $67,379,000.00 in 2018. The total inventory for QuidelOrtho was $67,078,000.00 in 2017. The total inventory for QuidelOrtho was $58,086,000.00 in 2019. The total inventory for QuidelOrtho was $27,639,000.00 in 2013. The total inventory for QuidelOrtho was $26,388,000.00 in 2015. The total inventory for QuidelOrtho was $26,045,000.00 in 2016. The total inventory for QuidelOrtho was $24,763,000.00 in 2014. The total inventory for QuidelOrtho was $198,800,000.00 in 2021. The total inventory for QuidelOrtho was $15,496,000.00 in 2012. The total inventory for QuidelOrtho was $113,798,000.00 in 2020. The sales, general, and administrative (SGA) for QuidelOrtho was $96,440,000.00 in 2017. The sales, general, and administrative (SGA) for QuidelOrtho was $77,458,000.00 in 2015. The sales, general, and administrative (SGA) for QuidelOrtho was $76,787,000.00 in 2016. The sales, general, and administrative (SGA) for QuidelOrtho was $68,887,000.00 in 2014. The sales, general, and administrative (SGA) for QuidelOrtho was $61,325,000.00 in 2013. The sales, general, and administrative (SGA) for QuidelOrtho was $50,119,000.00 in 2012. The sales, general, and administrative (SGA) for QuidelOrtho was $239,600,000.00 in 2021. The sales, general, and administrative (SGA) for QuidelOrtho was $200,543,000.00 in 2020. The sales, general, and administrative (SGA) for QuidelOrtho was $163,869,000.00 in 2019. The sales, general, and administrative (SGA) for QuidelOrtho was $153,938,000.00 in 2018. The sales, general, and administrative (SGA) for QuidelOrtho was $$621,000,000 in 2022. The revenue volatility for QuidelOrtho was 65.50% in 2022. The market capitalization for QuidelOrtho was $6,503,348,669.00 in 2016. The market capitalization for QuidelOrtho was $5,932,781,684.00 in 2019. The market capitalization for QuidelOrtho was $5,882,002,800.00 in 2013. The market capitalization for QuidelOrtho was $5,658,105,819.00 in 2018. The market capitalization for QuidelOrtho was $5,627,193,140.00 in 2014. The market capitalization for QuidelOrtho was $5,521,249,572.00 in 2020. The market capitalization for QuidelOrtho was $5,334,019,960.00 in 2012. The market capitalization for QuidelOrtho was $4,878,386,811.00 in 2021. The market capitalization for QuidelOrtho was $4,785,796,294.00 in 2017. The market capitalization for QuidelOrtho was $4,706,001,160.00 in 2015. The market capitalization for QuidelOrtho was $$4,673,000,000 in 2022. The gross revenue for QuidelOrtho was $534,890,000.00 in 2019. The gross revenue for QuidelOrtho was $522,285,000.00 in 2018. The gross revenue for QuidelOrtho was $277,743,000.00 in 2017. The gross revenue for QuidelOrtho was $196,129,000.00 in 2015. The gross revenue for QuidelOrtho was $191,603,000.00 in 2016. The gross revenue for QuidelOrtho was $184,158,000.00 in 2014. The gross revenue for QuidelOrtho was $177,325,000.00 in 2013. The gross revenue for QuidelOrtho was $155,741,000.00 in 2012. The gross revenue for QuidelOrtho was $1,698,600,000.00 in 2021. The gross revenue for QuidelOrtho was $1,661,668,000.00 in 2020. The gross revenue for QuidelOrtho was $$3,266,000,000 in 2022. The gross margin for QuidelOrtho was $30.00% in 2022. The days sales outstanding for QuidelOrtho was 46 days in 2022. The days payable outstanding for QuidelOrtho was 53 days in 2022. The days of inventory for QuidelOrtho was $99 in 2022. The cost of goods sold (COGS) for QuidelOrtho was 40.72% in 2022. The cost of goods sold (COGS) for QuidelOrtho was $79,872,000.00 in 2016. The cost of goods sold (COGS) for QuidelOrtho was $78,029,000.00 in 2015. The cost of goods sold (COGS) for QuidelOrtho was $74,180,000.00 in 2014. The cost of goods sold (COGS) for QuidelOrtho was $66,976,000.00 in 2013. The cost of goods sold (COGS) for QuidelOrtho was $61,285,000.00 in 2012. The cost of goods sold (COGS) for QuidelOrtho was $420,300,000.00 in 2021. The cost of goods sold (COGS) for QuidelOrtho was $312,813,000.00 in 2020. The cost of goods sold (COGS) for QuidelOrtho was $214,085,000.00 in 2019. The cost of goods sold (COGS) for QuidelOrtho was $206,572,000.00 in 2018. The cost of goods sold (COGS) for QuidelOrtho was $121,601,000.00 in 2017. The cost of goods sold (COGS) for QuidelOrtho was $$1,330,000,000 in 2022. The cash to cash cycle time for QuidelOrtho was 92 in 2022. The annual percentage growth rate of QuidelOrtho was -0.92% in 2022. QuidelOrtho in its benchmark peer group, had rank 7 for gross revenue in 2022. QuidelOrtho in its benchmark peer group, had rank 7 for cost of goods sold as a percent of revenue in 2022. QuidelOrtho in its benchmark peer group, had rank 3 for cash to cash cycle time in 2022. QuidelOrtho in its benchmark peer group, had rank 3 days for days sales outstanding in 2022. QuidelOrtho in its benchmark peer group, had rank 3 days for days of inventory in 2022. QuidelOrtho in its benchmark peer group, had rank 11 for sales growth in 2022. QuidelOrtho headquarters region is West. QuidelOrtho has ticker symbol QDEL. QuidelOrtho has the following profile: QuidelOrtho Corporation focuses on the development and manufacture of diagnostic testing technologies and solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units.. QuidelOrtho has primary indstury Medical Devices. QuidelOrtho had a $$469,000,000 gap between actual performance and next performance rank for gross revenue in competitive benchmarking in 2022. QuidelOrtho had Abbott Laboratories, and QuidelOrtho, and Zimmer Biomet, and Edwards Lifesciences, and Bio-Rad Laboratories, and Boston Scientific, and Align Technology, and Stryker, and AdaptHealth, and Bruker, and DexCom benchmark peer companies for its SIC code in 2022. QuidelOrtho had 7,000 number of employees in 2022. QuidelOrtho had 52.17% gap between actual performance and next performance rank for sales volatility in competitive benchmarking in 2022. QuidelOrtho had 5 days gap between actual performance and next performance rank for days of inventory in competitive benchmarking in 2022. QuidelOrtho had 3.48% gap between actual performance and next performance rank for cost of goods sold as a percent of revenue in competitive benchmarking in 2022. QuidelOrtho had 2 days gap between actual performance and next performance rank for days sales outstanding in competitive benchmarking in 2022. QuidelOrtho had 17 days gap between actual performance and next performance rank for cash to cash in competitive benchmarking in 2022. QuidelOrtho had 0.88% gap between actual performance and next performance rank for sales growth in competitive benchmarking in 2022. QuidelOrtho had 0.00% gap between actual performance and next performance rank for gross margin in competitive benchmarking in 2022. QuidelOrtho can reduce overall cost by $$114,000,000 by improving both COGS and SGA to next benchmark tier in 2022. QuidelOrtho can reduce inventory with practices including SKU Reduction in 2022. QuidelOrtho can reduce inventory with practices including Reduce Manufacturing Latency in 2022. QuidelOrtho can reduce inventory with practices including Forecast Accuracy in 2022. QuidelOrtho can reduce inventory with practices including Demand Shaping in 2022. QuidelOrtho can reduce days sales outstanding with practices including in 2022. QuidelOrtho can increase sales revenue by $$469,000,000 improving sales performance to next benchmark tier in 2022. QuidelOrtho can increase revenue growth by $$29,000,000 by improving growth performance to next benchmark tier in 2022. QuidelOrtho can increase overall revenue by $$497,000,000 by improving both growth and sales performance to next benchmark tier in 2022. QuidelOrtho can increase days payables outstanding with practices including Strategic Sourcing in 2022. QuidelOrtho can increase days payables outstanding by $63,000,000 days by increasing days payables outstanding to next benchmark tier in 2022. QuidelOrtho can improve total financial performance by $$736,000,000 by improving revenue, costs, and working capital in 2022. QuidelOrtho can decrease overall working capital by $$125,000,000 by improving inventory, payables and receivables to next benchmark tier in 2022. QuidelOrtho can decrease inventory days by $45,000,000 days by reducing inventory days to next benchmark tier in 2022. QuidelOrtho can decrease days sales outstanding by $18,000,000 days by reducing days sales outstanding to next benchmark tier in 2022. QuidelOrtho can accelerate revenue growth practices including Revenue-optimized Planning in 2022. QuidelOrtho can accelerate revenue growth practices including Pricing Optimization in 2022. QuidelOrtho can accelerate revenue growth practices including Accelerate Design Pipeline in 2022. 94 days was the measured superior or top ten performance level for days of inventory in QuidelOrtho's peer group in 2022. 9.89% was the measured superior or top ten performance level for sales volatility in QuidelOrtho's peer group in 2022. 75 days was the measured superior or top ten performance level for cash to cash cycle time in QuidelOrtho's peer group in 2022. 60 days was the measured parity or middle performance level for days sales outstanding in QuidelOrtho's peer group in 2022. 53 days was the measured advantage or top third performance level for days sales outstanding in QuidelOrtho's peer group in 2022. 44 days was the measured superior or top ten performance level for days sales outstanding in QuidelOrtho's peer group in 2022. 37.24% was the measured parity or middle performance level for cost of goods sold as a percent of revenue in QuidelOrtho's peer group in 2022. 31.56% was the measured advantage or top third performance level for cost of goods sold as a percent of revenue in QuidelOrtho's peer group in 2022. 30.00% was the measured superior or top ten performance level for gross margin in QuidelOrtho's peer group in 2022. 29.10% was the measured superior or top ten performance level for cost of goods sold as a percent of revenue in QuidelOrtho's peer group in 2022. 159 days was the measured parity or middle performance level for days of inventory in QuidelOrtho's peer group in 2022. 138 days was the measured parity or middle performance level for cash to cash cycle time in QuidelOrtho's peer group in 2022. 13.32% was the measured parity or middle performance level for sales volatility in QuidelOrtho's peer group in 2022. 119 days was the measured advantage or top third performance level for cash to cash cycle time in QuidelOrtho's peer group in 2022. 11.40% was the measured advantage or top third performance level for sales volatility in QuidelOrtho's peer group in 2022. 108 days was the measured advantage or top third performance level for days of inventory in QuidelOrtho's peer group in 2022. 0.04% was the measured superior or top ten performance level for sales growth in QuidelOrtho's peer group in 2022. -0.05% was the measured parity or middle performance level for sales growth in QuidelOrtho's peer group in 2022. -0.02% was the measured advantage or top third performance level for sales growth in QuidelOrtho's peer group in 2022. $18.02% was the measured advantage or top third performance level for gross margin in QuidelOrtho's peer group in 2022. $17.18% was the measured parity or middle performance level for gross margin in QuidelOrtho's peer group in 2022. $$6,940,000,000 was the measured advantage or top third performance level for gross revenue in QuidelOrtho's peer group. $$3,735,000,000 was the measured parity or middle performance level for gross revenue in QuidelOrtho's peer group in 2022. $$18,449,000,000 was the measured superior or top ten performance level for gross revenue in QuidelOrtho's peer group in 2022.